Can JNJ Sustain Growth Amid Patent, Legal and China Risks?

Johnson & Johnson faces several headwinds, led by Stelara losing U.S. patent exclusivity in 2025 and expected generic impact for Simponi and Opsumit starting in 2026. The company also continues to grapple with more than 75,000 talc lawsuits and ongoing China MedTech pressure from volume-based procurement, though it still targets about $100 billion in 2026 revenue and stronger growth thereafter. Consensus earnings estimates edged higher for 2026 to $11.57 and for 2027 to $12.60, partially offsetting the near-term operational and legal risks.

Analysis

The market is treating JNJ like a defensive compounder, but the next 4-6 quarters are really a portfolio transition story: legacy immunology cash flows are rolling off faster than the replacement basket can fully offset. That means the key question is not whether growth exists, but whether newer oncology/immunology assets can scale quickly enough to keep operating leverage intact while pricing and IRA effects continue to compress the bridge. In that setup, every incremental miss on the legacy franchise has an outsized effect on sentiment because the stock is still valued like a quality defensive with limited execution risk.

The second-order issue is competitive acceleration. Biosimilar entrants do not just pressure one molecule; they force payer contracting behavior across the class, which can pull forward share loss on adjacent immunology assets and weaken future launch economics for the same commercial team. In MedTech, China weakness is more important as a signal than as a direct profit driver: VBP pressure tends to normalize pricing expectations globally, so the risk is margin moderation even where volumes stabilize. That makes the bull case depend heavily on mix shift and cost discipline rather than broad-based end-market expansion.

The litigation overhang is still a valuation anchor because it keeps a structural discount on the multiple even when operating results improve. The hidden tail risk is not just adverse verdicts; it is management attention and capital allocation optionality being impaired for years, which can slow M&A or buybacks exactly when the company may need more aggressive portfolio rebalancing. Conversely, if the company can show two clean quarters of post-Stelara stabilization plus continued oncology momentum, the stock could re-rate mechanically because expectations are already cautious.

Key Decisions for Investors

• Stay underweight JNJ into the next 1-2 earnings prints; use any strength toward the high-teens forward multiple as an opportunity to reduce exposure, since the stock still embeds execution upside that the next few quarters may not validate.
• Pair trade: long AMGN / short JNJ for 3-6 months. AMGN is a cleaner relative beneficiary of biosimilar commercialization and should be less exposed to the legacy-growth reset; risk is AMGN specific pipeline disappointment, so keep size moderate.
• Avoid initiating fresh long JNJ positions until there is evidence that post-Stelara erosion is stabilizing; a better entry is after one quarter of visible inflection in Innovative Medicine growth, not on management commentary alone.
• For event-driven accounts, consider a JNJ put spread into earnings or litigation news flow with 60-90 day tenor. The structure benefits from downside re-rating if guidance or legal headlines disappoint, while capping premium outlay.
• Watch TEVA as a tactical beneficiary of biosimilar adoption, but prefer it only as a short-duration trade; the upside is more tied to product-cycle execution and less to durable franchise quality than AMGN.